Gilead, Merus to Collaborate on Trispecific Antibody Research
By Will Feuer
Gilead Sciences and Dutch biotechnology company Merus said they have struck a research collaboration, option and license deal to discover novel dual tumor-associated antigens targeting trispecific antibodies.
The companies said they will use Merus' proprietary Triclonics platform along with Gilead's oncology expertise to develop multiple, separate preclinical research programs.
Merus, which will lead early-stage research activities for two programs with an option to pursue a third, will get an upfront cash payment of $56 million for initial targets. Gilead will also buy $25 million worth of Merus shares.
Across all potential programs, Merus is eligible to receive up to $1.5 billion including additional near term and option payments, potential development and commercialization milestones, as well as tiered royalties if Gilead commercializes any therapies from the research.
Gilead will have the right to license programs developed under the collaboration after the completion of select research activities.
Gilead said the deal will likely reduce its adjusted and non-adjusted 2024 earnings by 3 cents a share to 5 cents a share.
"We have seen the successful application of bispecific antibodies as an immune-modulating modality used to treat cancer," said Flavius Martin, executive vice president of research at Gilead. "We are now looking ahead to the development of additional multispecific antibodies capable of driving robust anti-tumor immune responses with an improved efficacy and safety profile."
Write to Will Feuer at Will.Feuer@wsj.com
(END) Dow Jones Newswires
March 06, 2024 08:38 ET (13:38 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
After Earnings, Is Home Depot Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is Baidu Stock a Buy, a Sell, or Fairly Valued?
-
Why Stocks Are Hitting Record Highs—and What Could Send Them Back to Earth
-
5 Stocks to Buy While They’re Trading at Big Discounts
-
Markets Brief: Tech Stocks Lead Ahead of Nvidia Earnings
-
How Anti-Obesity Drugs Are Innovating the Healthcare Market
-
What’s Happening In the Markets This Week
-
Why Immigration Has Boosted Job Gains and the Economy
-
After Earnings, Is Walmart Stock a Buy, a Sell, or Fairly Valued?
-
Target Earnings: Margins Hold Up, but Top Line Constrained by Weak Discretionary Spending
-
Is Berkshire Hathaway’s Mystery Stock a Buy?
-
After Earnings, Is Uber Stock a Buy, a Sell, or Fairly Valued?
-
Lowe’s Earnings: Tumultuous Macro Weighs on Near-Term Results but Fails to Sway Our Long-Term View
-
Macy’s Earnings: Plan Taking Shape Despite Tough Environment
-
JPMorgan Investor Day: CEO Dimon Pushes Against More Stock Buybacks at Current Prices
-
Should You Buy and Hold an Artificial Intelligence Portfolio?